[Etranacogene dezaparvovec (haemophilia B): Review of the study protocol (Version 4.0) and the statistical analysis plan (Version 4.0) – Fourth addendum to Project A22-83 (RPDC concept)]
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018015802
German
Original Title:
Etranacogen Dezaparvovec (Hämophilie B): Prüfung des Studienprotokolls (Version 4.0) und des statistischen Analyseplans (Version 4.0) – 4. Addendum zum Projekt A22-83 (AbD-Konzept)
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a26-21.html
Year Published:
2026
URL for published report:
https://www.iqwig.de/download/a26-21_etranacogen-dezaparvovec_addendum-zum-projekt-a22-83_v1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Hemophilia B
- Genetic Therapy
- Factor IX
- Registries
- Research Design
- Gene Therapy Agents
Keywords
- Etranacogene Dezaparvovec
- Hemophilia B
- Benefit Assessment
- Registries
- Research Design
- Peer Review – Research
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.